Introduction
The treatment of epilepsy can be a very frustrating task. About 25% of epilepsy patients are refractory to all classical anti-epileptic drugs. William G. Lennox reported in 1928 ''One who is confronted with the task of controlling seizures in a person with epilepsy grasps at any straw''. In that context many alternative treatments have been used in former days from powdered human skull, to gall bladder of a boar dried with urine, or blood or liver of a recently slain gladiator. Currently, beside classical anti-epileptic drugs, some less conventional therapies are utilized in the treatment of intractable seizures, as there are ketogenic diet, immunoglobulins, steroids and vagus nerve stimulation. 1 Adrenocorticotrophic hormone (ACTH) was first reported to have beneficial effects in the treatment Seizure (2005) Summary Steroids and adrenocorticotrophic hormone (ACTH) have been used for the treatment of infantile spasms for several years. However, the use of steroids in the treatment of epilepsy beyond infantile spasms has been limited to only a few studies. We report the experience with steroids in 32 children with intractable epilepsy, not including West syndrome. In 47% there was a decrease in seizure frequency, 25% became seizure free, 11% had a seizure reduction of >50% and 11% had a seizure reduction of <50%. Our study confirms the conclusions of few previous reports of effective adjunctive steroid treatment for children with intractable epilepsy. The possible side effects, however, especially during prolonged therapy remain an important concern. # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
of children with intractable seizures in 1950. 2 Eight years later, its specific therapeutic activity in infantile spasms was described. 3 Subsequently numerous reports demonstrated the effect of ACTH or steroids in West syndrome. Since the mechanism of action of ACTH or steroids in infantile spasms is unknown, it is controversial whether ACTH is superior to glucocorticoids or not. Some studies have reported that ACTH and prednisone have similar efficacy, 4, 5 whereas others have found ACTH to be more effective. 6, 7 A recent review of the treatment of infantile spasms concluded that ACTH and vigabatrine were most effective in infantile spasms but that there was concern about the safety-profile. 8 Apart from West syndrome, there are few reports about the use of steroids in children with intractable epilepsy. We report the experience with oral steroids or intramuscular ACTH for the treatment of children with intractable epilepsy, excluding children with West syndrome.
Methods
A retrospective assessment was made of all pediatric patients who were treated with steroids for intractable epilepsy at the Ghent University Hospital, Epilepsy and Rehabilitation Center Pulderbos and the Academic Hospital of Brussels between 1993 and 2003. Patients with West syndrome and patients who received a single dose for status epilepticus were excluded.
A total of 32 patients (16 boys, 16 girls) were included, of which 3 patients had two to three courses of treatment with steroids. All patients had failed first and second line anti-epileptic medication. Patient's medical charts were studied. Gender, age at onset epilepsy, age at start of treatment, seizure type, seizure frequency, EEG and MRI abnormalities, mental status, etiology, previous anti-epileptic drugs and type, dose and duration of steroid therapy, effect of steroid therapy on seizure frequency, EEG and cognition, and side effects were registered. Duration of follow-up was between 6 months and 8 years with a mean followup period of 36 months.
Results
Patient's characteristics are listed in Table 1 . Thirtytwo patients (16 males/16 females) were included. Mean age at onset epilepsy was 2.6 year (males 1.5/ females 3.7) and mean age at treatment with steroids was 4.7 year (males 3.8/females 5.7). Prior to steroid treatment, all patients received 2-10 different anti-epileptic drugs. Most patients had frequent seizures with 21 patients having at least one seizure a day and 6 others having at least one seizure a week. In one patient, overt seizures were not noticed and because of sub-coma, change of consciousness could not be appreciated while the EEG was strongly indicative of an ictal event. In the entire group, the seizure types were very diverse including absences, atypical absences, tonic, clonic, tonic-clonic, myoclonic, atonic, simple partial, complex partial and secondary generalized seizures. All patients had epileptiform abnormalities in the EEG records. MRI was normal in 14 and abnormal in 17 patients of which 11 had post-ischemic, postinfection or post-hemorrhagic lesions. In one patient, MRI results were not available. Other etiologic diagnoses are trisomy 21, ceroid lipofuscinosis, Alpers disease, pyridoxine-dependent seizures, hemimegalencephaly, Landau-Kleffner syndrome (LKS) and electrical status epilepticus in sleep (ESES). At the time of treatment all patients were mentally retarded. Six patients were initially mentally normal but regressed. Of the remaining 26 patients, another 20 patients showed mental regression during active epilepsy.
Of the 32 treated patients, 3 had two to three courses of treatment with steroids because of persistent or recurrent seizures. We evaluated 36 treatment courses. The type of therapy given differed from one center to another. Thirteen treatment courses with dexamathasone (doses of 0.5-5 mg/ kg/d and duration from 3 days to 8 months, continue or in pulse therapy) were reported, ten with hydrocortisone (doses of 5-20 mg/kg/d and duration from 4 weeks to 20 months), eight with prednisone (doses of 0.3-3 mg/kg/d and duration from 7 days to 24 months), one with methylprednisolone (dose of 2 mg/kg/d and duration 2 months) and four with ACTH (doses of 2-5 IU/kg/d and duration 3 weeks). Duration of follow-up was between 6 months and 8 years with a mean follow-up period of 36 months.
Of the total of 36 treatment courses, 17 lead to a clinically significant response and 19 did not. Thirteen (36%) patients were responders of whom nine (25%) became seizure free and four (11%) had a reduction in seizure frequency of more than 50%. Another four (11%) had a reduction in seizure frequency of less than 50%. The 17 patients with clinically significant response are listed in Table 2 . Of the nine patients with seizure freedom during therapy, three remained seizure free after long-term followup (28 months to 4 years). Six of the nine relapsed, one after 10 months and five during the first month after stop steroids. However, four of the six patients with relapse seizures still had a residual seizure control of more than 50% at the end of follow-up (1-8 year). Of the overall group of 13 responders, 8 had still a seizure frequency reduction of more than 50%, of which 3 were seizure free, at the end of the study (1-8 year follow-up). A positive effect on EEG recordings (normalization, decrease in epileptiform activity, improvement of background activity) was noticed in 15 of the 36 treatment courses and in all of the 13 responders. In the 19 patients without reduction in seizure frequency, improvement of EEG was only noticed in 2. Cognitive or behavioral improvement was noticed in 21 of the 36 treatment courses, including all of the 13 responders. Of the four patients with seizure frequency reduction less than 50%, two had a positive effect on cognition, and, of the nineteen without reduction in seizure frequency, six were more alert or had better behavior.
There was no difference in gender, mean age at onset epilepsy, mean age at therapy, time interval between first seizures and therapy, seizure type, seizure frequency, findings on EEG or MRI, mental status, presence of regression and etiological diagnosis between responders and non-responders. The only factor that correlates with becoming seizurefree was a longer duration of treatment, independently of the type of steroid. Of the nine patients who became seizure-free, two were treated with ACTH, five with hydrocortisone and two with prednisone. The duration of hydrocortisone or prednisone therapy (including tapering off) was at least 6 months of continuous treatment in each of those patients. Of the 19 patients without any clinically significant response, 13 were treated for less than 4 weeks, 2 between 4 weeks and 6 months and only 4 longer than 6 months. Although, it should be mentioned that in two patients steroid therapy was stopped after 4 weeks because of lack of response.
Side effects were noticed in 23 of the 36 treatment courses and included obesity (6), increased weight (5) or improved appetite (3), Cushing syndrome (7), behavioral disturbance (4), hypertension (3), hypokalaemia (1), femur fracture (1) and cardiac decompensation (1). Steroid therapy had to be discontinued in one patient due to side effects. A positive correlation between duration of treatment and side effects was found. Of the 17 courses with continuous treatment of more than 4 weeks, 16 had side effects including the most severe side effects. Of those who received less than 4 weeks continuous steroid therapy (15) , only 5 had milder side effects. In those treated with ACTH (4), 2 were reported with side effects. Of the 17 courses with continuous treatment of more than 4 weeks, 10 were treated with hydrocortisone, 6 with prednisone or methylprednisolone and 1 with dexamethasone. No correlation was seen between type of steroid and number and severity of side effects.
Discussion
Steroids and adrenocorticotrophic hormone have been used in the treatment of infantile spasms for several years 3 . The option of treating with ACTH or steroids is still the subject of ongoing controversy, [4] [5] [6] [7] [8] and not only the type of steroid but also its dosage, timing and duration remain undefined. 9 The use of steroids in the treatment of epilepsy beyond infantile spasms has been limited to only a few studies. 6, [10] [11] [12] Good response to ACTH was described in Ohtahara syndrome 13 and in Lennox-Gastaut syndrome.
14 Steroids or other immunomodulating therapies are reported to be effective in Landau-Kleffner syndrome and in electrical status epilepticus in sleep.
15-19 Snead et al. described their experience in 64 children with intractable epilepsy--other than infantile spasms--treated with either ACTH or prednisone. Most patients had myoclonic seizures. Treatment was successful in 74% of those treated with ACTH and in none of those treated with prednisone (3 mg/kg/d for 12 weeks). This finding made the author assume that the mechanism of action was extra-adrenal and that ACTH had a direct effect on neuronal function. 6 Hasaerts et al. presented a retrospective study of 32 children with secondary generalized epilepsy treated with hydrocortisone 5 mg/kg/d for 1 month, tapered during at least 6 months. Half of the children exhibited significant reduction of seizure frequency and in 2/3 cognitive abilities improved. Results were better in tonic and tonic-clonic seizures than in absences. 10 Sinclair reported his experience with prednisone (1 mg/ kg/d for 12 weeks--6 weeks daily and 6 weeks on alternate days) in 28 children older than 1 year with intractable epilepsy. Thirteen patients (46%) became seizure free and another ten (36%) had a significant decrease in seizure frequency. Best outcomes were seen in absence seizures and LennoxGastaut syndrome.
11
In our study, a retrospective assessment was made of 36 courses of steroid treatment in a heterogeneous pediatric population with intractable epilepsy. Due to the contribution of three different centers and due to the retrospective character of this study, different types of steroids in different dosages and durations were given. Of the 36 courses of treatment, 17 (47%) showed a clinically significant response of whom 9 (25%) became seizure free, 4 (11%) had a seizure reduction of >50% and 4 (11%) had a seizure reduction of <50%. Moreover, after stop steroid therapy, 8 (22%) remained good responders with 3 (8%) still seizure free and 5 (14%) having a reduction in seizure frequency of >50% (follow-up 1-8 year). EEG, cognitive and behavioral improvement was observed in all responders. We found no correlation between seizure type and outcome possibly due to the heterogeneity of the sample group. Also no correlation could be seen between type of steroid used and effect on epilepsy or cognition. The only factor that seems to correlate with becoming seizure free was longer duration of treatment, which conforms to findings in literature. Good results of steroid therapy in the study of Hasaerts et al. 10 and Sinclair 11 were also obtained with prolonged therapy of respectively 6 months and 12 weeks.
On the other hand, we found more frequent and more severe side effects in patients receiving steroid therapy for more than 4 weeks. During 16/17 courses (94%) with treatment duration of more than 4 weeks, side effects were reported. In one patient with cardiac decompensation, therapy had to be stopped. Hasaerts et al. reported side effects in 56% 10 and Sinclair in 28%.
The anti-seizure mechanism of action of corticosteroids or ACTH is unknown. ACTH has both endocrine and neuromodulatory properties. Firstly, ACTH, as a neuropeptide, may have anti-convulsive properties by itself. 9 Secondly, ACTH may act by stimulation of glucocorticoid synthesis. Glucocorticoids are thought to interact with central nervous system steroid recep- Figure 1 Decision tree when dealing with children with intractable epilepsy.
tors that act as transcriptional regulators 20 and to influence voltage-dependent calcium channels. 21 Thirdly, ACTH may exert a positive effect by neurosteroid synthesis in glial cells and neurons. ACTH induces the synthesis of deoxycorticosterone (DOC) a precursor of dihydrodeoxy-corticosterone (DHDOC) and tetrahydrodeoxy-corticosterone (THDOC). DHDOC and THDOC are both allosteric modulators of GABA A receptors. 22 Down regulation of corticotropin releasing hormone (CRH) expression may also be of importance, given the proconvulsant activity of CRH in the immature brain. 23 Last but not least, ACTH as well as corticosteroids have immunomodulatory properties. Immunomodulation has been suggested as the mechanism of action in LandauKleffner syndrome and ESES, which are assumed to be autoimmune diseases of the brain. 19 For the same reason high-dose steroids are used in Rasmussen's encephalitis. 24 Endogenous steroid hormones, mainly synthesized in the adrenal glands, the gonads and the feto-placental unit, can easily cross the bloodbrain barrier due to their high lipid solubility and act as neuroactive steroids. Estrogens exacerbate seizures whereas progesterone is protective. The physiological premenstrual decrease of progesterone and its metabolites may cause catamenial seizures as well as psychic changes in the premenstrual period. 25 In vivo progesterone may be converted into highly neuroactive compounds, in particular allopregnanolone. Allopregnanolone is a very potent positive-allosteric modulator of the GABA A receptor complex. 26 Interestingly the human hippocampus is equipped with enzymes that are necessary for sex steroid formation and metabolism. Cholesterol can be converted to the potent neurosteroid allopregnanolone in human hippocampus, temporal lobe and other human brain regions. 27 Naturally occurring neuroactive steroids undergo rapid biotransformation upon exogenous administration. Ganaxolone, a 3-beta-methylated synthetic analogue was designed to overcome this pharmacokinetic limitation. 28 Ganaxolone is as potent as allopregnanolone in modulating GABA A receptors but has no hormonal function. In humans, ganaxolone showed a promising pharmacokinetic profile and was well tolerated in a trial with 96 healthy volunteers. 29 The steroid proved to be well tolerated and effective in the first clinical studies with epilepsy patients. [30] [31] [32] Double-blind randomized studies are necessary to establish the future role for ganaxolone in clinical practice.
As practical instrument when dealing with children with intractable epilepsy, we tried to make a decision tree (Fig. 1) . Since no class I evidence is available about this topic due to lack of prospective, controlled, randomized studies, this decision tree is empiric and meanly based on our own clinical experience. Alternative therapies are used when children do not respond to classical anti-epileptic drugs, are no good candidates for epilepsy surgery and when seizures or EEG disturbances are frequent disabling daily live. Vagus nerve stimulation is a palliative therapy only used when 'medicinal' therapy failed including immunotherapy and/or ketogenic diet. Ketogenic diet is preferable in some specific metabolic disorders like pyruvate dehydrogenase (PDH) deficiency 33 or Glut-1 deficiency syndrome 34 and in some patients with predominant seizure types other than complex partial. 35 Immunotherapy is classically used in West syndrome. [4] [5] [6] [7] [8] It is also described, with less evidence, in LennoxGastaut syndrome, 14 Landau-Kleffner syndrome and electrical status epilepticus during sleep, [15] [16] [17] [18] [19] Rasmussen encephalitis 24 and Ohtahara syndrome. 13 In our experience, children with cognitive regression and behavior problems due to their epilepsy are good candidates too for immunotherapy. When starting immunotherapy, a choice has to be made between intravenous immunoglobulins and steroids. Since in our country intravenous immunoglobulins are expensive and not reimbursed in the indication epilepsy, we first go for a trial with steroids. Known contraindications for steroid therapy are severe concurrent infections, hypertension, diabetes, osteoporosis and growth retardation. Since there are, nor in literature, neither in our own experience, no significant arguments in favor of ACTH intramuscular above oral administration of steroids we propose to treat orally, avoiding in this way discomfort and hospitalization. A possible suggestion is a trial of 4 weeks with hydrocortisone 10 mg/ kg/d. We prefer hydrocortisone above other steroids because of less mineralocorticoid effect. A 4-week trial is long enough to evaluate possible positive effect and is short enough to minimalize side effects.
If not effective, a fast tapering should follow in order to prevent severe side effects. When effective, a more gentle decrease in dose, over a period of months to even years, is necessary to maintain the positive effect. Rate of tapering can be influenced by possible side effects or relapses of epilepsy.
Conclusion
Our study confirms previous reports of the effectiveness of adjunctive steroid treatment for children with intractable epilepsy. Side effects, especially of prolonged therapy, remain an important concern.
